{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:42:07Z","timestamp":1761061327626,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010438","name":"statutory funding for young researchers\u2014doctoral students for 2024","doi-asserted-by":"publisher","award":["132\/2024\/DGB"],"award-info":[{"award-number":["132\/2024\/DGB"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background: The number of publications related to rivaroxaban is growing, making it difficult for scientists to review relevant materials. Objectives: This bibliometric analysis is focused on highlighting hot spots and new trends associated with rivaroxaban studies and provides references and guidance for further research. Methods: A comparison between countries, journals, authors, and organizations was performed. Microsoft Excel 2021 and VOSviewer were used to process and visualize data extracted from Web of Science. The time range was set from 1991 to late 2024. A total of 6979 articles were analyzed and bibliometric maps of co-citations of references and co-occurrences of the keywords were built. Results: Relative research interest increased until 2021, when it started to drop. The new trends in publications related to rivaroxaban are associated with a comparison of NOAC therapy outcomes with previously used vitamin K antagonists (warfarin). The research was focused also on new NOAC representatives, medical conditions treated with NOAC, and safety of the therapy. New trending topics are related to ABCB1, peripheral artery disease, direct-acting oral anticoagulants, PCI, and SARS-CoV-2. Conclusions: This bibliometric analysis showed that increasing attention is being paid to the medical conditions treated with NOACs and issues related to the safety of this therapy.<\/jats:p>","DOI":"10.3390\/clinpract15100190","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:24:02Z","timestamp":1761056642000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends and Hot Spots in Research Related to Rivaroxaban: Bibliometric Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-6276","authenticated-orcid":false,"given":"Kornel","family":"Pawlak","sequence":"first","affiliation":[{"name":"Department of Physical Pharmacy & Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka Street 3, 60-806 Poznan, Poland"},{"name":"Doctoral School, Poznan University of Medical Sciences, Bukowska Street 70, 60-812 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-5765","authenticated-orcid":false,"given":"\u0141ukasz","family":"Kruszyna","sequence":"additional","affiliation":[{"name":"Department of Vascular & Endovascular Surgery, Angiology and Phlebology, Poznan University of Medical Sciences, Dluga St. 1\/2, 61-848 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-2265","authenticated-orcid":false,"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka Street 3, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-7035","authenticated-orcid":false,"given":"Marta","family":"Kara\u017aniewicz-\u0141ada","sequence":"additional","affiliation":[{"name":"Department of Physical Pharmacy & Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka Street 3, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40256-024-00638-4","article-title":"Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020","volume":"24","author":"Alkhezi","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_5","first-page":"640723","article-title":"Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups","volume":"2013","year":"2013","journal-title":"Thrombosis"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Abdel-Razeq, H., and Al-Jaghbeer, M.J. (2024). Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Cancer Patients with Central Venous Catheters: A Literature Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061660"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ruig\u00f3mez, A., Schink, T., Voss, A., Herings, R.M.C., Smits, E., Swart-Polinder, K., Balabanova, Y., Brobert, G., Suzart-Woischnik, K., and Rodr\u00edguez, L.A.G. (2024). Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298596"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Escobar, C., Palacios, B., Villarreal, M., Guti\u00e9rrez, M., Capel, M., Hern\u00e1ndez, I., Garc\u00eda, M., Lled\u00f3, L., and Arenillas, J.F. (2024). Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061677"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4212\/cjhp.v70i4.1681","article-title":"Rivaroxaban-Induced Hypersensitivity Syndrome","volume":"70","author":"Chiasson","year":"2017","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_10","unstructured":"Al-Khafaji, R.A. (2024, June 25). Developing Deep Venous Thrombosis While on Rivaroxaban: A Review of Rivaroxaban. Available online: https:\/\/www.hilarispublisher.com\/open-access\/developing-deep-venous-thrombosis-while-on-rivaroxaban-a-review-of-rivaroxaban-45389.html."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/rheumatology\/kex086","article-title":"Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome","volume":"56","author":"Dufrost","year":"2017","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: Pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40246-023-00506-3","article-title":"The impact of ABCB1, CYP3A4\/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation","volume":"17","author":"Wu","year":"2023","journal-title":"Hum. Genom."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s10557-023-07495-4","article-title":"Mutant CYP3A4\/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation","volume":"38","author":"Li","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000143832.91812.60","article-title":"Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2","volume":"110","author":"Spiecker","year":"2004","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the Breast Cancer Resistance Protein (BCRP\/ABCG2) in Drug Transport\u2014An Update","volume":"17","author":"Mao","year":"2014","journal-title":"AAPS J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Baturina, O., Chashkina, M., Andreev, D., Mirzaev, K., Bykova, A., Suvorov, A., Yeryshova, D., Suchkova, S., Sychev, D., and Syrkin, A. (2023). Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy. J. Pers. Med., 13.","DOI":"10.3390\/jpm13091371"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wo\u0142owiec, \u0141., Kusiak, M., Budzy\u0144ski, J., Wo\u0142owiec, A., Ja\u015bniak, A., Wici\u0144ski, M., Pedrycz-Wieczorska, A., Rogowicz, D., and Grze\u015bk, G. (2023). Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight\u2014Pilot Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12154969"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1021\/acs.analchem.8b02046","article-title":"Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS\/MS-Based Assay","volume":"90","author":"Foerster","year":"2018","journal-title":"Anal. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trac.2016.01.029","article-title":"Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?","volume":"84","author":"Douxfils","year":"2016","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Margeti\u0107, S., \u0106elap, I., Kes, V.B., Lovren\u010di\u0107-Huzjan, A., Kobasi\u0107, I., Goreta, S.\u0160., Pavlovi\u0107, N., and Brklja\u010di\u0107, D.D. (2020). Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: Possibilities and limitations. Biochem. Med., 30.","DOI":"10.11613\/BM.2020.010702"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pawlak, K., Kruszyna, \u0141., Miecznikowska, M., and Kara\u017aniewicz-\u0141ada, M. (2024). Application of a Novel UPLC-MS\/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis. Molecules, 29.","DOI":"10.3390\/molecules29174140"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/acs.analchem.9b04063","article-title":"Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots","volume":"92","author":"Jhang","year":"2020","journal-title":"Anal Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5603\/AHP.a2021.0039","article-title":"Therapeutic monitoring of direct oral anticoagulants\u2014An 8-year observational study","volume":"52","year":"2021","journal-title":"Acta Haematol. Pol."},{"key":"ref_26","first-page":"111","article-title":"Analysis of Citations and Co-Citations of the Term \u2018Word of Mouth\u2019 Based on Publications in the Field of Social Sciences","volume":"48","year":"2023","journal-title":"Mark. Sci. Res. Organ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/1094428114562629","article-title":"Bibliometric Methods in Management and Organization","volume":"18","author":"Zupic","year":"2015","journal-title":"Organ. Res. Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: An overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J. Bus. Res."},{"key":"ref_29","unstructured":"VOSviewer (2024, September 23). VOSviewer\u2014Visualizing Scientific Landscapes. Available online: https:\/\/www.vosviewer.com\/\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14604582211043158","DOI":"10.1177\/14604582211043158","article-title":"Trend research of vitamin D receptor: Bibliometric analysis","volume":"27","author":"Abouzid","year":"2021","journal-title":"Health Inform. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1055\/s-0040-1718892","article-title":"Research Trends in Anticoagulation Therapy over the Last 25 Years","volume":"46","author":"Mian","year":"2020","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e029810","DOI":"10.1161\/JAHA.123.029810","article-title":"Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20\u2009Years: A Bibliometric Analysis Via CiteSpace and VOSviewer","volume":"12","author":"Miao","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Song, W., Ma, T., Cheng, Q., Wen, P., Wu, J., Hao, L., Zhang, B., Wang, Y., Wang, Q., and Zhang, Y. (2022). Global Research Status and Trends in Venous Thromboembolism After Hip or Knee Arthroplasty From 1990 to 2021: A Bibliometric Analysis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.837163"},{"key":"ref_34","first-page":"7","article-title":"Pulmonary circulation: What has 2010 brought?","volume":"47","year":"2011","journal-title":"Arch. Bronconeumol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gao, Y., Wang, Y., Zhai, X., He, Y., Chen, R., Zhou, J., Li, M., and Wang, Q. (2017). Publication trends of research on diabetes mellitus and T cells (1997\u20132016): A 20-year bibliometric study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184869"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101714","DOI":"10.1016\/j.jacadv.2025.101714","article-title":"A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and\/or Venous Thromboembolism","volume":"4","author":"Schaefer","year":"2025","journal-title":"JACC Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.mayocpiqo.2024.05.004","article-title":"Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution","volume":"8","author":"Cohen","year":"2024","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): An open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.14871","article-title":"Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience","volume":"18","author":"Testa","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.15537\/smj.2024.45.4.20230728","article-title":"Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19","volume":"45","author":"Shen","year":"2024","journal-title":"Saudi Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/leap.1545","article-title":"Enter the dragon: China and global academic publishing","volume":"36","author":"Hyland","year":"2023","journal-title":"Learn. Publ."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2008.07.015","article-title":"Determination of rivaroxaban\u2013A novel, oral, direct Factor Xa inhibitor\u2014In human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"872","author":"Rohde","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kuhn, J., Gripp, T., Flieder, T., Dittrich, M., Hendig, D., Busse, J., Knabbe, C., and Birschmann, I. (2015). UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145478"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jth.12702","article-title":"Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography\u2014Tandem mass spectrometry (UPLC-MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants","volume":"12","author":"Schmitz","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Derogis, P.B.M., Sanches, L.R., de Aranda, V.F., Colombini, M.P., Mangueira, C.L.P., Katz, M., Faulhaber, A.C.L., Mendes, C.E.A., Ferreira, C.E.d.S., and Fran\u00e7a, C.N. (2017). Determination of rivaroxaban in patient\u2019s plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS\/MS). PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171272"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/10\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:31Z","timestamp":1761059191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/10\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["clinpract15100190"],"URL":"https:\/\/doi.org\/10.3390\/clinpract15100190","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}